The purpose of this study is to assess the bioequivalence and food effect for a new Premarin formulation compared with a Premarin reference tablet in Japanese healthy postmenopausal women.

Inclusion Criteria:

• Japanese healthy postmenopausal women

Exclusion Criteria:

• History or current evidence of thrombophlebitis, thromboembolic disorders, or any coagulopathies.
• History or presence of malignancy or estrogen-dependent neoplasia. Subjects with a documented history of any malignancy, except for basal or squamous cell carcinoma of skin, which has been treated and fully resolved for a minimal 5 years.
• History or presence of benign or malignant liver tumor that developed during the use of oral contraceptives or other estrogen-containing products.